These four Dividend Aristocrats are Buy-rated sector leaders with yields above 3%. Passive income investors can buy and hold ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion.

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus ...

The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in partnership with Enanta Pharmaceuticals, Inc.

AbbVie (NYSE:ABBV) recently secured FDA approval for the expanded use of MAVYRET, a treatment for hepatitis C, which now includes those with acute HCV. This development is significant as it broadens ...

MAVYRET and other medicines may affect each other. This can cause you to have too much or not enough MAVYRET or other medicines in your body.

MAVYRET is now approved for both acute and chronic HCV infection in adults and pediatric patients three years and older without cirrhosis or with compensated cirrhosis. While the company maintains ...

NORTH CHICAGO - The U.S. Food and Drug Administration has approved a label expansion for AbbVie’s (NYSE: ABBV) MAVYRET, making it the first and only oral treatment approved for acute hepatitis C virus ...

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET ® (glecaprevir ...